Physician profile
Vilma Herrera
NPI 1861840514
$1,925.78
in general payments reported to CMS, 2019-2025
7 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $191 · 2022: $154 · 2023: $552 · 2024: $852 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,580.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $748.67 | 2023-2025 | Krystexxa, Otezla, Tavneos |
| Horizon Therapeutics Plc | $506.40 | 2021-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $192.10 | 2021-2025 | Acthar |
| Kiniksa Pharmaceuticals, LTD. | $135.00 | 2023 | Arcalyst |
| Pfizer INC. | $127.21 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2023 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $91.40 | 2024 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vilma Herrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.